A
AMLX
Amylyx Pharmaceuticals
18.17
+0.20+1.11%After Hours: 18.49 +0.32 +1.76%19:15 07/07 EDT
OPEN/PREV CLOSE18.04/17.97
TODAY RANGE17.75-18.59
VOL1.52M
MARKET CAP2.02B
52 WEEK RANGE6.14-19.15
AVG VOL (3M)1.36M
% TURNOVER1.36%
TURNOVER--
P/E (TTM)-12.0595
% RANGE4.67%
EPS(TTM)-1.5067
P/E(FORWARD)-12.7509
P/B7.39
BVPS2.460
DIVIDEND--
P/S11.08
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.71B
SHARES OUTSTANDING111.19M
NEXT EARNINGS08/05-08/10
FREE FLOAT94.10M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·20h ago
Is Amylyx Pharmaceuticals (AMLX) A Bargain Following Russell Index Removals?
Simply Wall St·2d ago
Index Exit and Early ALS Data Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)
Simply Wall St·06/27 15:13
Could Amylyx (AMLX) ALS Safety Data Quietly Reframe Its Neurodegeneration Versus Endocrine Strategy?
Simply Wall St·06/26 14:13
Amylyx Pharmaceuticals (AMLX) Reports Early LUMINA Safety Data, Is The Stock Still Below Fair Value?
Dow Jones·06/25 14:19
Amylyx Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones·06/25 14:19
Amylyx Pharmaceuticals Price Target Raised to $40.00/Share From $30.00 by Guggenheim
Benzinga·06/25 14:12
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $40
TipRanks·06/25 11:30
Amylyx price target raised to $40, named a Best Idea at Guggenheim
TipRanks·06/24 11:35
H.C. Wainwright Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
TipRanks·06/23 12:10
Amylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial
Same Industry
Name/Symbol
Change%
Price